<DOC>
	<DOC>NCT02157948</DOC>
	<brief_summary>This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.</brief_summary>
	<brief_title>A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subject has provided informed consent prior to any studyspecific activities/procedures Ambulatory postmenopausal women. Age 55 years or older Screening BMD value equivalent to a Tscore less than or equal to 2.5 at the lumbar spine, total hip, or femoral neck. Administration of osteoporosis treatments or bone active treatments within specific timeframes Vitamin D deficiency Diseases and conditions that affect bone metabolism (e.g., hypo/hyperparathyroidism; hypo/hyperthyroidism, unless stable and wellcontrolled) Contraindications to denosumab therapy (e.g., hypocalcemia)</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>postmenopausal osteoporosis</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>denosumab</keyword>
	<keyword>women</keyword>
</DOC>